The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
Site Search
Showing 1 - 10 of 48 results
News
|
May 6, 2011
|
1 min read
Press Release
|
Nov. 2, 2011
|
2 min read
News
|
Nov. 8, 2011
|
2 min read
News
|
Nov. 17, 2010
|
3 min read
News
|
Sept. 16, 2008
|
1 min read
News
|
April 11, 2008
|
1 min read
News
|
Aug. 20, 2008
|
1 min read
News
|
Aug. 11, 2014
|
2 min read
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
News
|
Aug. 7, 2018
|
3 min read
Meb Keflezighi, one of the world's best runners, joined Lee University and ran in the 65 Roses 5K in Cleveland, Tenn. to support the fight against cystic fibrosis. Lee University was thrilled to welcome him as part of its longstanding tradition of raising funds in support of the CF Foundation's mission.
News
|
April 16, 2018
|
3 min read